BuKwang Pharm, Q1 Revenue 47.8 Billion Won...Operating Profit 1.1 Billion Won
BuKwang Pharm reported Q1 revenue of 47.8 billion won and operating profit of 1.1 billion won, while its subsidiary Contera Pharma entered Phase 2 clinical trials.
Key takeaway
"BuKwang Pharm, Q1 Revenue 47.8 Billion Won...Operating Profit 1.1 Billion Won" — BullBear's AI rates this story as a mixed, direction-neutral signal, with a market-impact score of 15 out of 100. BuKwang Pharm reported Q1 revenue of 47.8 billion won and operating profit of 1.1 billion won, while its subsidiary Contera Pharma entered Phase 2 clinical trials. Reported by Maeil Business on April 21, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Get the next high-impact catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 53.3%.